Trademarkia Logo

Canada

C$
LEBVANAH
ADVERTISED

on 17 Feb 2025

Last Applicant/ Owned by

Eli Lilly and Company

Lilly Corporate CenterIndianapolis, IN 46285

US

Serial Number

2098493 filed on 8th Apr 2021

Registration Number

TMA1290985 registered on 17th Feb 2025

Registration expiry Date

17th Feb 2035

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

LEBVANAH

Trademark usage description

pharmaceutical preparations namely pharmaceutical preparations for the treatment of alopecia, alzheimer's disease, atopic dermatitis, autoimmune disea Read More

Classification Information


Class [005]
Pharmaceutical preparations namely pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders namely osteoporosis, osteoarthritis, fracture healing, bone frailty due to extended ventilator use, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, arthritis, bursitis, tendonitis, osteonecrosis and Paget's disease, cancer, cardiovascular diseases, central nervous system diseases and disorders namely, anxiety disorders, depression, bipolar depression, bipolar disorder, treatment resistant depression, schizophrenia and cognitive impairment associated with schizophrenia, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders namely psoriasis, skin cancer and eczema, diabetes, dyslipidemia, endocrine diseases and disorders, namely Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders namely inflammatory bowel diseases, inflammatory connective tissue diseases and rheumatoid arthritis, kidney diseases and disorders, liver diseases and disorders, lupus, mental diseases and disorders, namely mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, and cerebral palsy, metabolic diseases and disorders namely metabolic syndrome, migraines, neurodegenerative diseases and disorders namely Huntington's disease, Alzheimer's disease, and dementia, neurological disorders namely Alzheimer's disease, mild cognitive impairment, Parkinson's disease and multiple sclerosis, obesity, osteoarthritis, pain relief, Parkinson's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; vascular diseases; Diagnostic agents, preparations and substances for medical diagnostic purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases.


Classification kind code

12

Mark Details


Serial Number

2098493

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 190
on 17th Feb 2025
Registration Pending
Submitted for opposition 42
on 27th Nov 2024
Advertised
Submitted for opposition 26
on 30th Oct 2024
Approved
Submitted for opposition 27
on 30th Oct 2024
Approval Notice Sent
Submitted for opposition 22
on 22nd Oct 2024
Search Recorded
Submitted for opposition 287
on 30th Jun 2022
Pre-Assessment Letter Sent
Submitted for opposition 48
on 1st Feb 2022
Agent Changed
Submitted for opposition 30
on 8th Apr 2021
Filed
Submitted for opposition 1
on 8th Apr 2021
Created
Submitted for opposition 31
on 8th Apr 2021
Formalized